- Trial Phase
- Phase 3 (completed) / Pre-BLA submission
- Time to Market
- If approved, potential US launch for ages 4-7 in mid-to-late 2027; toddler indication (1-3) would follow later via accelerated approval pathway
- Why 6/10
- BLA submission for ages 4-7 expected Q3 2026 (within ~3 months) — not a binary approval decision, but a hard, dated milestone that starts the FDA clock for a drug that is essentially DBVT's entire enterprise value. The real binary (PDUFA) would land ~mid-2027, just within the 12-month window if submission is early Q3.
Watch for the official BLA submission announcement in Q3 2026, which will trigger a 10-month FDA review and the assignment of a PDUFA date. The stock trades 130%+ below the analyst consensus mean price target of ~$40.85, but dilution risk from the $150M ATM program is real. The BLA submission delay from H1 to Q3 2026 is a modest negative but the FDA did not request new data, which reduces regulatory risk.
Price Chart
Executive Summary
DBV Technologies' VIASKIN Peanut Patch is an investigational epicutaneous immunotherapy (EPIT) patch for peanut allergy — a once-daily skin patch that desensitizes the immune system. After an FDA rejection in 2020 (Complete Response Letter citing patch adhesion concerns), DBV redesigned the patch and delivered two successful Phase 3 programs (EPITOPE in toddlers 1-3, VITESSE in children 4-7). The company is now preparing to resubmit a Biologics License Application (BLA) to the FDA for ages 4-7 in Q3 2026, with an accelerated approval pathway also secured for toddlers 1-3. The stock is essentially a single-asset bet on this approval. With a mean analyst price target of ~$40.85 (131% upside from ~$15.82), strong institutional holders (Baker Bros., Artisan Partners), and a large underserved market — but also significant cash burn, ATM dilution risk, and the lingering stain of the 2020 CRL — Viaskin represents a high-conviction, high-risk binary opportunity.
How It Works
A skin patch worn daily on the back that delivers microgram amounts of peanut protein through intact skin. The goal is to gradually train the immune system to tolerate small amounts of peanut, reducing the risk of severe allergic reactions from accidental ingestion. Unlike oral immunotherapy (which involves eating peanut powder), the patch is non-invasive and has a lower risk of triggering serious allergic reactions.
Trial Status
The VITESSE Phase 3 trial in ages 4-7 met its primary endpoint in Dec 2025 (46.6% responder rate vs 14.8% placebo). The EPITOPE Phase 3 trial in ages 1-3 completed with 3-year OLE data showing 68.2% of toddlers passed an oral food challenge. A supplemental safety study (COMFORT Toddlers) for the accelerated approval pathway in toddlers is ongoing. BLA submission for 4-7-year-olds originally planned H1 2026, now targeted for Q3 2026 after productive FDA feedback — no additional data requested.
The Two-Sided Case
Upcoming Catalysts
- BLA submission for ages 4-7 (Q3 2026) — the formal FDA filing that starts the 10-month review clock
- Potential PDUFA date assignment (late 2026 / early 2027) — the hard binary approval decision
- COMFORT Toddlers supplemental safety study readout for 1-3 age group accelerated approval
- BLA submission for toddlers 1-3 under accelerated approval pathway (anticipated 2H 2026)
- EAACI Congress 2026 — additional VITESSE data and THRIVE study preview
Source Filing
The SecBot filing or press-release report that triggered this drug report:
DBV Technologies S.A. 8-K DBVT ·Originating report